NCT06297434View on ClinicalTrials.gov

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

PHASE2RecruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

April 15, 2025

Study Completion Date

October 30, 2025

Conditions

Non-alcoholic Steatohepatitis

Interventions

DRUG

J2H-1702

Orally, once daily before meals

DRUG

J2H-1702

Orally, once daily before meals

DRUG

J2H-1702

Orally, once daily before meals

DRUG

Placebo

Orally, once daily before meals

Trial Locations (1)

16684

RECRUITING

J2H Biotech, Suwon

Sponsors

Lead Sponsor

All Listed Sponsors

lead

J2H Biotech

INDUSTRY